Revealed: In Vivo's 2024 Rising Leaders
30 people to watch from across the life sciences sector
VIEW NOWFeatured Stories
Synthetic Biology Matures, Promising Affordable And Personalized Treatments
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
Apogee CMO On New Approach To I&I Market
Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.
Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline
Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.
Latest Articles
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.